Rare diseases
Investigational molecules
Locations
346 conditions with trials, the busiest first
960 trials across Europe, recruiting first
Study on the Effectiveness of Apalutamide in Men with Castration-Resistant Prostate Cancer
AustriaStudy on Elinzanetant for Treating Sleep Disturbances in Menopausal Women
AustriaStudy of Dostarlimab for Patients with High-Risk Locally Advanced Cervical Cancer After Chemo-Radiation
SpainStudy of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer
AustriaStudy Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment
AustriaStudy of Olaparib and Abiraterone for Men with Advanced Prostate Cancer Resistant to Hormone Therapy
BelgiumStudy on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy
AustriaStudy on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy
AustriaStudy of Olaparib for Patients with Advanced BRCA-Mutated Ovarian Cancer After Initial Platinum-Based Chemotherapy
FranceStudy on Testosterone Undecanoate Effects on Liver Fat in Obese Men with Low Testosterone and Type 2 Diabetes or Prediabetes
AustriaStudy of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy
FranceStudy of LN-145 (tumor infiltrating lymphocytes) with cyclophosphamide, fludarabine, and aldesleukin in patients with recurrent, metastatic, or persistent cervical cancer
FranceThe therapies tested most often in Reproductive system and breast disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
